RxDoctor Payments Data

Michael Ring, MD

Interventional Cardiology · Spokane, WANPI 1467455543

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Medtronic at 46.2% of the total. Reporting peaked in 2019 at $21,611 and has fallen 99.6% since, to $97 in 2024.

$47,146in general payments, 2019–2025

Across 72 payments — averaging $654.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$22K
  • Boston Scientific$20K
  • Amgen$5K
  • Shockwave Medical, Inc$128
  • Edwards Lifesciences$127
  • Abbott$122
  • plus $97 from 2 others
$22,301in research payments, 2019–2025

Across 43 payments — averaging $518.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Daiichi Sankyo Inc.$15K
  • Medtronic$8K

What the payments were for

  • Consulting fees$15,90034%
  • Speaking & faculty fees$24,68852%
  • Travel & lodging$3,3347%
  • Food & beverage$3,2107%
  • Education$140%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)33$21,781
Boston Scientific29$19,794
Amgen3$5,096
Shockwave Medical, Inc2$128
Edwards Lifesciences2$127
Abbott1$122
Abiomed1$83
Pfizer1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,146 in reported general payments places this provider in the 85th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$34,843
Medicare patients
524
Services billed
775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate26$208

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →